CurrentBlue Cross Blue Shield - IowaPolicy N/A

Vertebral Augmentation

Policy governing medical necessity and coverage of vertebral augmentation procedures (e.g., percutaneous vertebroplasty, balloon kyphoplasty, mechanical vertebral augmentation, radiofrequency kyphoplasty, sacroplasty, expandable interbody implants) for members of Blue Cross Blue Shield - Iowa (Wellmark). Applies to use for osteoporotic or osteolytic vertebral compression fractures and sacral insufficiency fractures.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyVertebral Augmentation

Policy CodePolicy N/A

Change TypeAnnual review (no material change)

Effective DateApr 1, 2017

Next Review DateN/A

Key ActionDocument fracture age, imaging confirmation, prior conservative therapy (usually ≥6 weeks) and symptom severity when submitting for coverage review.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2017Original effective year

6 weeksConservative therapy

>7Significant pain threshold

8Listed indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Network meta-analysis RCTs

Coverage Criteria for Vertebral Augmentation

Descriptive clinical and device information

Descriptive clinical and device information — background on procedures, devices, and materials relevant to percutaneous vertebral augmentation and sacroplasty.

Vertebroplasty is a percutaneous procedure involving injection of bone cement (eg, polymethylmethacrylate, Cortoss®) into a fractured vertebra to provide mechanical stabilization and pain relief. Balloon kyphoplasty uses an inflatable bone tamp to restore vertebral height prior to cement injection. Radiofrequency kyphoplasty (radiofrequency-targeted vertebral augmentation) creates channels within the vertebra and uses radiofrequency to control ultra-high viscosity cement viscosity during injection. Mechanical vertebral augmentation devices (eg, Kiva®, SpineJack®) deploy an implant to create a cavity or structural support within the vertebral body that is subsequently filled with cement, aiming to reduce cement leakage and/or improve height restoration.

Polymethylmethacrylate bone cements have evolved through FDA regulation; several cements have 510(k) clearance for fixation of pathologic fractures of the vertebral body using vertebroplasty or kyphoplasty. Use of bone cement in sacroplasty is considered an off-label application of those clearances. Specific devices (eg, KyphX® inflatable bone tamp, Kiva VCF Treatment System, SpineJack, StabiliT® system) have received 510(k) clearances for specific indications. The OptiMesh® Expandable Interbody Fusion System has FDA 510(k)/De Novo classifications for vertebral body defect graft containment (not as a direct vertebral augmentation for typical osteoporotic VCFs).

Adverse events across vertebral augmentation procedures primarily relate to cement leakage, with potential sequelae including radiculopathy, cord compression, infection (eg, osteomyelitis), pulmonary embolism, or procedure-related sedation/transfer complications. Procedural success and safety may be influenced by fracture age, fracture morphology (eg, extent of vertebral body destruction, presence of intravertebral cleft), bone quality, and operator technique (volume/type of cement, device selection).

Sacroplasty applies vertebroplasty-like cement injection techniques to sacral insufficiency fractures using short-axis, long-axis, or balloon-assisted approaches. Evidence for sacroplasty is limited to observational series and registries; randomized controlled trials are lacking. Off-label use considerations and limited evidence of harms mean sacroplasty remains less well characterized than vertebroplasty/kyphoplasty.

Percutaneous vertebral augmentation — guideline stance

Percutaneous vertebral augmentation — summary of guideline positions and practice guidance relevant to coverage and appropriate use.

Multiple specialty societies and guideline bodies have issued statements regarding vertebral augmentation:

- The American College of Radiology (ACR) and collaborating societies (2014; updated appropriateness criteria 2022) support offering percutaneous vertebral augmentation (vertebroplasty or kyphoplasty) for appropriate patients with symptomatic osteoporotic or neoplastic fractures when nonoperative therapy has failed or pain is significantly affecting quality of life; appropriateness varies by clinical scenario (eg, symptomatic osteoporotic VCF with marrow edema is usually appropriate).

- The Society of Interventional Radiology (SIR) quality improvement guideline (2014) defines failure of medical therapy in several clinical contexts and emphasizes that procedures be considered when analgesic therapy is insufficient or intolerable and when pain prevents ambulation or participation in therapy.

- The American Academy of Orthopaedic Surgeons (AAOS) 2011 guideline issued a strong recommendation against routine use of vertebroplasty for acute osteoporotic compression fractures in neurologically intact patients, reflecting RCT evidence of uncertain benefit in some settings.

Coding and Codes Referenced

Covered CPT CodesCPT

22510	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic.
22511	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral.
22512	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure).
22513	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic.
22514	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar.
22515	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine (e.g., may be utilized for Expandable Interbody Implant ).

Sacroplasty Category III CodesCPT

0200T	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed.
0201T	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed.

Sacroplasty HCPCS / C-Code Mappingsmixed

C1062	Intravertebral body fracture augmentation with implant (e.g., metal, polymer).
C7504	Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance.
C7505	Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance.
C7507	Percutaneous vertebral augmentations, first thoracic and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (e.g., kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance.
C7508	Percutaneous vertebral augmentations, first lumbar and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (e.g., kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance.

FDA 510(k) numbers and device clearances referencedmixed

K080108	Cortoss® Bone Augmentation Material 510(k) number
K160983	KYPHON® HV-R® Bone Cement 510(k) number
K033801	KyphX® HV-RTM 510(k) number
K043593	Spine-Fix® Biomimetic Bone Cement 510(k) number
K181752	Stryker iVAS Elite Inflatable Vertebral Augmentation System 510(k) number

Device identifiers and FDA summaries mentionedmixed

K143006	GUARDIAN-SG Inflatable Bone Expander System referenced
K162453	K162453 mapping referencing multiple kyphoplasty/augmentation devices (e.g., MEDINAUT, AVAflex, Osseoflex entries)
K141141	Kiva VCF Treatment System referenced
K181262	SpineJack Expansion Kit referenced
K191709	V-Strut Vertebral Implant referenced

See Codes tablemixed

No codes listed

The policy and supporting trials define key clinical thresholds used in evaluating candidates: significant pain is a pain rating (VAS/NRS) of > 7 or severe/disabling pain; documentation should reference these measures when asserting medically necessary indications.

The policy requires documentation of prior conservative therapy in most cases: an adequate trial is generally defined as >= 6 weeks of optimal conservative management (prescription‑strength analgesics/steroids/NSAIDs, bracing, and provider‑directed exercise) unless an exception applies (for example, acute fractures <6 weeks causing hospitalization or preventing ambulation).

Trials used enrollment thresholds that may inform documentation: pivotal device and comparative trials enrolled patients with high baseline pain and disability (examples include VAS ≥70 mm after 2–6 weeks of conservative care or VAS ≥50 mm after 6 weeks, and ODI ≥30%), and these trial thresholds are referenced in the policy as examples of populations studied.

To adequately evaluate outcomes and mirror trial follow‑up, the policy indicates a recommended minimum follow‑up duration of >= 1 year for assessment of primary outcomes in osteolytic vertebral compression fracture studies and related device evaluations.

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior approval / documentation note

Prior approval: Not applicable for this policy, but when prior authorization is required by the payer, submit full medical records as described below. Documentation should clearly reference the specific intended augmentation procedure and device/implant to be used.

If prior authorization is required by Blue Cross Blue Shield - Iowa follow payer-specific submission process and include all items listed under Required Documentation.

Documentation Required

Device clearance documentation

Document the specific device or implant to be used and include evidence of FDA clearance (eg, 510(k) number) when applicable. For marketed devices (balloon tamps, mechanical augmentation systems, expandable implants, proprietary cements), include device name, manufacturer, and clearance documentation.

List the device/implant trade name, manufacturer, and 510(k) number or other FDA marketing clearance information where available (eg, KyphX® inflatable bone tamp Kxxxxxx; StabiliT® Vertebral Augmentation System).

Background, Definitions and Scope

Vertebral augmentation encompasses a range of percutaneous techniques — including percutaneous vertebroplasty, balloon kyphoplasty, mechanical vertebral augmentation systems (e.g., Kiva, SpineJack), radiofrequency‑targeted vertebral augmentation, sacroplasty, and expandable interbody implants — intended to stabilize fractures and reduce pain. The policy’s scope covers treatment of symptomatic osteoporotic or osteolytic vertebral compression fractures and sacral insufficiency fractures and summarizes evidence across these methods to inform coverage decisions.

Definitions — Procedures & Implants

Definitions — Other Terms & Sacral Techniques

Clinical Evidence Summary and Limitations

Evidence-summary criteria

Study-based populations and key outcome findings (used to inform coverage decisions):

Sham-controlled RCT population: Adults with 1–3 painful osteoporotic vertebral compression fractures, pain duration ≤12 months, baseline pain thresholds as required by individual trials, randomized to vertebroplasty versus sham.

Buchbinder, Kallmes, Firanescu trials summarized

Sham-controlled RCT outcomes: Pooled sham-controlled trials generally found no significant between-group differences in VAS or disability scores at multiple time points; some trials reported subgroup benefits (e.g., VAPOUR in acute thoracolumbar fractures).

See trial-specific summaries and pooled analyses.

Randomized trials and comparative studies summarized in the policy show mixed results. Some RCTs (including VAPOUR and several open‑label trials) reported early pain relief and functional improvements after augmentation compared with conservative care, whereas pooled sham‑controlled trials generally failed to show consistent between‑group differences. Meta‑analyses and systematic reviews report heterogeneity across studies and limitations that temper interpretation of aggregate outcomes.

References, Guidelines and Position Statements

The document references clinical guidelines and specialty society statements (ACR, AAOS, NICE, SIR, ASPN, and others) addressing indications, appropriateness, and safety considerations for percutaneous vertebral augmentation to inform policy interpretation and procedural expectations.

Guideline input summarized in the policy varies by society: for example, the ACR supports augmentation in appropriately selected symptomatic osteoporotic and neoplastic fractures after failed conservative therapy, AAOS issued a strong recommendation against vertebroplasty for neurologically intact acute osteoporotic fractures, and ASPN supports augmentation for symptomatic metastatic fractures — illustrating that specialty guidance differs and should be considered alongside trial evidence when making coverage decisions.

The policy includes a comprehensive reference list of the evidence base (systematic reviews, randomized trials, observational studies, and guidelines) that underpins the coverage analysis and is available to support clinical review and appeals.

Policy Revision History

2025-06Annual review and renewalLatest

Policy underwent annual review and was renewed.

2024-06Annual review and revision

Policy underwent annual review and was revised.

2023-06Annual review and revision

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyVertebral Augmentation

Policy CodePolicy N/A

Change TypeAnnual review (no material change)

Effective DateApr 1, 2017

Next Review DateN/A

Key ActionDocument fracture age, imaging confirmation, prior conservative therapy (usually ≥6 weeks) and symptom severity when submitting for coverage review.

SourceLink

On This Page

- The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) guideline (2020) does not recommend vertebroplasty or kyphoplasty as first-line treatments for vertebral fractures due to unclear overall benefit and potential adjacent-fracture risk.

- The American Society of Pain and Neuroscience (ASPN) recommends strongly considering vertebral augmentation for symptomatic metastatic vertebral compression fractures (evidence level 1-A) but notes limited data to prefer vertebroplasty versus kyphoplasty.

- NICE guidance (2013 and subsequent updates) supports considering vertebroplasty/kyphoplasty in selected patients with severe, ongoing pain after recent unhealed vertebral fracture despite optimal pain management, and in selected patients with spinal metastases without cord compression when instability or uncontrolled pain is present.

Guideline themes relevant to coverage determinations:

- Reserve augmentation procedures for patients with documented, localized, clinically significant pain attributable to the fractured level, confirmed by imaging (eg, MRI showing bone marrow edema or intravertebral cleft) and where other causes of pain have been excluded;

- Require documentation of prior conservative management and its duration except in specific circumstances (eg, hospitalized patients with severe pain preventing ambulation, or fractures <6 weeks with hospitalization or inability to ambulate);

- Recognize heterogeneity in the evidence: sham-controlled trials have yielded mixed results (benefit seen in some acute severe pain subgroups), while nonblinded trials and meta-analyses often show short-term pain and functional improvements; absence of sham-controlled trials for kyphoplasty and mechanical augmentation limits certainty;

- Highlight the need for appropriate patient selection (fracture age, extent of vertebral body destruction, bone quality) and procedural expertise to minimize harms such as cement leakage.

Operational implication: coverage decisions should align with guideline recommendations by requiring documentation of imaging-confirmed symptomatic fracture at the treated level, exclusion of alternative pain sources, trial and failure of conservative therapy where indicated, and consideration of exception criteria (eg, severe pain preventing ambulation or hospitalization within 6 weeks).

If an investigational or non–FDA-cleared device is proposed, note that coverage may be denied as investigational.

Prior Authorization

Prior authorization: imaging and conservative therapy documentation

For prior authorization, provide imaging confirmation of the fracture (preferably MRI demonstrating bone marrow edema or correlating acute/subacute change) and documentation of failed conservative therapy where required by indication.

Attach completed reports of diagnostic imaging (MRI, CT, radiographs) localizing the treated level(s) and showing fracture age and characteristics.
Document conservative care attempted (medication trials, bracing, physical therapy) including start/end dates and response.

Prior Authorization

Prior authorization: specify technique and conservative care status

Specify the exact vertebral augmentation technique proposed (vertebroplasty, balloon kyphoplasty, radiofrequency-targeted augmentation, Kiva, SpineJack, sacroplasty) and clearly state whether conservative care has been tried and failed or the reason conservative care is being bypassed (eg, nonambulatory due to pain, hospitalization).

Include operative plan describing approach, levels, laterality, type of cement/injectate, and use of balloons, implants, or mechanical devices.
If conservative care is being exempted (eg, <6 weeks with hospitalization or inability to ambulate), provide documentation to support exemption.

Documentation Required

Prior authorization: clinical criteria referenced

When prior authorization decisions reference trial-based clinical criteria, include objective baseline measures and threshold values used in trials (eg, pain scores, ODI/RMDQ) to support medical necessity.

Provide baseline pain score (VAS/NRS) and functional measures (Oswestry Disability Index, Roland-Morris Disability Questionnaire) with dates.
Note duration of symptoms and timeframe of conservative care relative to trial entry criteria (eg, ≥6 weeks of conservative therapy for many RCT inclusion criteria).

Prior Authorization

Prior conservative care and surgical candidacy

Prior conservative care is generally required before augmentation unless the patient meets surgical candidacy exemptions (eg, severe pain preventing ambulation or hospitalization). Document failure or intolerance of conservative therapy and assess surgical candidacy consistent with society guidance.

Document trial of optimal conservative therapy (see Conservative Therapy) including analgesics, bracing, and provider-directed exercise for >6 weeks when applicable.
When claiming surgical candidacy, provide clinical notes describing functional limitations, inability to participate in PT, or unacceptable analgesic side effects.

Prior Authorization

Prior authorization: show failed conservative therapy and imaging

For prior authorization, include a clear statement demonstrating failure of conservative therapy and attach correlated imaging that confirms the treated fracture(s). Imaging should support fracture acuity when required (eg, MRI bone marrow edema for fractures between 6 weeks and 1 year).

Attach imaging demonstrating level(s) to be treated and report dates; MRI is preferred to corroborate acuity/subacute changes.
Include treatment timeline showing conservative measures tried and objective evidence of persistent, debilitating pain despite those measures.

Billing Rule

Prior authorization and code list

Follow payer-specific prior authorization processes and ensure coding matches the performed procedure. Use the CPT and Category III codes listed in the policy when submitting authorization and claims.

Submit appropriate CPT codes such as 22510–22515 (vertebroplasty/augmentation) and unlisted spine 22899 when applicable.
For sacroplasty use Category III codes 0200T/0201T and reference associated HCPCS mappings (C1062, C7504–C7508) per policy tables.

Denial Risk

Denial triggers

Denial triggers include lack of documentation meeting the medical necessity criteria, procedures performed outside the covered indications (eg, cervical spine, thoracic T1–T4, prophylactic use), or use of techniques/devices considered investigational.

Claims may be denied if records do not document failed conservative therapy when required, or if imaging does not confirm the symptomatic fracture at the treated level.
Procedures for noncovered indications (eg, prophylactic augmentation, nonpainful hemangiomas, sacroplasty for sacral lesions when considered investigational by this policy) risk denial.

Denial Risk

Safety-related denial risk

Safety-related denial risk: cement or injectate leakage and device-related complications are principal safety concerns. Insufficient documentation of risk mitigation, informed consent, or absence of contraindications may prompt additional review or denial.

Document assessment and plan to minimize cement extravasation and management plans for potential complications.
Report any prior adverse events or anatomical factors increasing risk of leakage; lack of such documentation may lead to scrutiny.

Note

High crossover, lack of blinding, or failed trial limitations

Evidence limitations: RCTs with high crossover, lack of blinding in some trials, and methodological heterogeneity complicate interpretation of benefit. When relying on such evidence, provide clear rationale and individualized documentation of expected benefit.

Trials with substantial crossover (eg, control-to-procedure crossover rates) weaken intention-to-treat analyses — document why the patient differs from trial populations if using observational evidence to justify treatment.
Be explicit about why sham-controlled trial limitations (eg, unblinding due to anesthetic effects) do not preclude benefit for this patient.

Note

Evidence base for sacroplasty lacks randomized trials

Sacroplasty evidence lacks randomized trials and is based primarily on observational series with small numbers and methodological limitations. Justify use of sacroplasty by documenting failure or insufficiency of conservative management and the clinical rationale for intervention.

Provide detailed clinical history, pain scores, functional impairment, prior conservative measures and duration, and rationale for choosing sacroplasty despite limited RCT evidence.
Note potential higher uncertainty regarding long-term harms given limited sample sizes in published series.

Documentation Required

Studies with duplicative or overlapping populations

Avoid using studies with duplicative or overlapping populations to justify coverage. Ensure referenced literature and registries represent independent cohorts and document how the patient's presentation aligns with nonoverlapping study populations.

If citing institutional series or registries, disclose overlap with prior published cohorts and provide independent supporting data when possible.

Documentation Required

Procedure and material documentation

Procedure and material documentation: include planned materials (type/brand of cement or injectate), volume estimates, and any adjunctive devices (balloon, implant, tamp). Operative consent and device-specific training or credentialing details may be requested.

Specify cement type (eg, PMMA, proprietary formulations), expected volume, and whether biopsy is planned.
Include documentation of operator credentialing or institutional privileging for device-specific techniques if available.

Documentation Required

Required clinical documentation

Required clinical documentation: the submission should include diagnosis, onset and duration of symptoms, baseline pain and functional scores, prior conservative care with dates, imaging reports, and absence of alternative causes of pain (eg, spinal canal compression).

Document that the pain is localized to the treated level and that other causes (eg, disk herniation or spinal stenosis) have been ruled out by CT or MRI.
Include note on vertebral body integrity (eg, at least one-third of original height remaining) when applicable to eligibility criteria.

Documentation Required

Providers should document fracture confirmation

Providers should document fracture confirmation (preferably MRI demonstrating bone marrow edema or intravertebral cleft for symptomatic fractures), pain duration, and correlation between imaging and clinical exam.

For fractures between 6 weeks and 1 year, include imaging demonstrating subacute changes (bone marrow edema) and clinical notes correlating pain to that level.
For acute fractures (<6 weeks) that bypass conservative care requirement due to hospitalization or inability to ambulate, include supporting hospital records.

Documentation Required

Document symptomatic osteoporotic vertebral compression fractures

Document symptomatic osteoporotic vertebral compression fractures with objective measures of pain and functional impairment and show that conservative care was attempted and failed when required by criteria.

Include VAS/NRS pain scores and functional indices (ODI, RMDQ) with dates to demonstrate severity and refractory nature of symptoms.

Documentation Required

Clinical documentation should include diagnosis and follow-up measures

Clinical documentation should include diagnosis, baseline pain/function measures, prior conservative care and response, imaging/lab support when applicable, and any contraindications to conservative therapy.

When treating metastatic or neoplastic lesions, document oncologic treatment plan and timing of radiotherapy/chemotherapy relative to proposed augmentation.

Documentation Required

Documentation to support medical necessity

Documentation to support medical necessity may reference trial inclusion thresholds (eg, minimum pain scores, ODI thresholds) but must be individualized. Provide objective pre-procedure measures and planned postprocedure follow-up assessments.

Supply baseline and planned follow-up assessment schedule (eg, VAS and ODI at 1 month, 6 months, 12 months) to allow outcome tracking.
If using device-specific trials to justify coverage, demonstrate how the patient meets the trial entry criteria.

Step Therapy

Document prior conservative management and imaging follow-up

Document prior conservative management and imaging follow-up consistent with trial protocols when applicable. Records should show duration, type, and adequacy of conservative therapy before considering augmentation.

Conservative therapy examples: prescription-strength analgesics/steroids/NSAIDs, bracing, and a provider-directed exercise program for >6 weeks unless exempted.
If conservative therapy was intolerable or contraindicated, provide documentation of adverse effects or clinical inability to participate.

Documentation Required

Documentation should demonstrate failure of conservative therapy

Documentation should demonstrate failure of conservative therapy using explicit definitions where available (eg, Society of Interventional Radiology failure definitions) or show clinical circumstances meeting exemption criteria (eg, nonambulatory after 24 hours of analgesia).

Use clear timelines and objective evidence (progress notes, pain scores, functional declines) to demonstrate refractoriness to conservative care.
If applying SIR failure definitions, include documentation of attempts at analgesia and the resulting level of functioning or intolerance.

Step Therapy

Conservative therapy requirement

Conservative therapy requirement: optimal conservative therapy (analgesics, bracing, and provider-directed exercise) is generally required for a minimum of 6 weeks for symptomatic osteoporotic or steroid-induced fractures unless specific exemption criteria are met.

Document dates and specifics of conservative measures; absence of adequate conservative therapy without documented exemption may lead to denial.

Step Therapy

Conservative therapy first

Conservative therapy first: conservative management is appropriate as first-line care for many fracture types and for metastatic lesions where radiotherapy/chemotherapy are expected to address symptoms; document rationale if augmentation is selected earlier.

When augmentation is performed prior to expected effect of oncologic therapies, document rationale (eg, imminent risk of collapse, refractory pain despite initial cancer-directed therapy).

Note

Evidence from nonblinded and blinded RCTs

Evidence from nonblinded and blinded RCTs is mixed; when relying on trial data to support treatment, acknowledge methodological limitations (heterogeneity, underpowered outcomes) and provide individualized justification.

Cite relevant trial criteria and explain how the patient's clinical picture aligns with favorable trial subgroups if applicable.

Note

Conservative management is the primary comparator

Conservative management is the primary comparator in trials and should be documented as the comparator attempted prior to augmentation when appropriate.

List conservative modalities tried (PT, analgesics, bracing, bed rest) and outcomes for each modality.

Documentation Required

Conservative care (bed rest, analgesia, bracing, exercise)

Conservative care examples to document include bed rest, analgesia, bracing, and provider-directed exercise programs. Record duration and response for each modality.

Specify medication names/doses, brace type and wear schedule, and PT session dates and objectives.

Step Therapy

Step therapy: conservative care precedes augmentation in trials

Step therapy: in many trials, conservative care preceded augmentation, implying an operational step-therapy approach. Prior authorization should reflect that conservative care was attempted per the policy unless an exemption is documented.

If requesting an exception to step therapy, include documentation supporting exemption criteria (eg, hospitalized due to fracture-related pain).

Step Therapy

Prior conservative therapy

Prior conservative therapy: reiterate and document prior conservative care attempts and outcomes before approval of augmentation procedures unless clear exemption criteria apply.

Include dates, response, and reasons for discontinuation of prior conservative therapies.

Note

Comparators of interest include conservative management

Comparators of interest include conservative management modalities; when using observational evidence showing benefit over conservative care, document distinctions between the study population and the individual patient.

Explain why the patient is expected to derive benefit relative to conservative management given their specific clinical features.

Note

Consideration of conservative management

Consideration of conservative management: multiple specialty societies recommend considering conservative care prior to augmentation; document adherence to or justified deviation from society recommendations.

If deviating from society guidance, provide detailed clinical justification in the chart.

Evidence syntheses indicate that kyphoplasty and mechanical augmentation (Kiva, SpineJack) can produce short‑term improvements in pain and function versus conservative care in some trials; device trials (for example, Kiva vs kyphoplasty) have shown noninferiority on composite endpoints, and observational meta‑analyses have reported mortality associations, but the absence of sham controls for many device trials and heterogeneity across studies limit definitive conclusions about comparative effectiveness.

Overall, the policy concludes that available clinical evidence shows short‑term pain and functional benefits in some patient groups but also has important limitations — heterogeneity of study designs, lack of sham controls for many interventions, potential placebo effects, selective reporting, and variable follow‑up — which restrict confidence in long‑term net health benefit for some indications.

Comparative analyses of radiofrequency‑assisted techniques versus conventional balloon kyphoplasty include a meta‑analysis and at least one randomized trial: the meta‑analysis suggested greater immediate pain reduction with radiofrequency techniques, but the RCT found no significant difference at 12 months. These mixed comparative findings indicate that additional high‑quality studies are needed to clarify whether radiofrequency‑assisted augmentation provides meaningful advantages.

The policy states that expandable interbody implants lack randomized controlled trial evidence for traumatic fracture repair and interbody fusion; available data are limited to a small retrospective study and nonrandomized reports, and thus the net health benefit is unestablished — a conclusion important for coverage consideration.

Hayes’ technology assessment and other external evidence appraisals are cited to contextualize trial quality and consistency; these assessments highlighted limited or inconsistent evidence for devices such as Kiva in certain populations and reinforced the overall cautionary interpretation of available data.

The policy highlights the lack of sham‑controlled trials for many device and kyphoplasty comparisons as a key evidence gap. Sham‑controlled RCTs that exist did not consistently demonstrate clinically meaningful advantage for vertebroplasty versus sham, which is an important limitation when interpreting non‑sham randomized and observational findings.

Pooled analyses and the individual sham‑controlled randomized trials (Buchbinder, Kallmes, Firanescu) raised concerns that vertebroplasty provided no clinically significant benefit over sham in many outcome measures, with both active and sham groups showing improvements and limited between‑group differences at several time points; these findings underpin the policy’s cautious stance on routine use in populations similar to those trials.

Policy underwent annual review and was revised.

2022-04Annual review and revision

Policy underwent annual review and was revised.

2021-04Annual review and revision

Policy underwent annual review and was revised.

2020-06Interim review and revision

Policy received an interim review and was revised.

2020-04Annual review and revision

Policy underwent annual review and was revised.

2019-04Annual review and revision

Policy underwent annual review and was revised.

2018-04Annual review and revision

Policy underwent annual review and was revised.

2017-04New policy effective

Policy was created and became effective as a new policy.